AgomAb Therapeutics (NASDAQ:AGMB) Earns Buy Rating from Analysts at B. Riley Financial

Equities researchers at B. Riley Financial began coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research report issued on Thursday. The firm set a “buy” rating and a $34.00 price target on the stock. B. Riley Financial’s price objective points to a potential upside of 193.10% from the company’s previous close.

Separately, HC Wainwright assumed coverage on AgomAb Therapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, AgomAb Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $33.00.

AgomAb Therapeutics Stock Performance

AgomAb Therapeutics stock opened at $11.60 on Thursday. The business has a 50-day simple moving average of $11.71. AgomAb Therapeutics has a twelve month low of $8.75 and a twelve month high of $17.82.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.